Cardinali, Daniel P.; Vidal, María F.; Vigo, Daniel E.

New developments in the treatment of primary insomnia in elderly patients: focus on prolonged-release melatonin


Cómo citar el documento:


(Se recomienda indicar fecha de consulta al final de la cita. Ej: [Fecha de consulta: 19 de agosto de 2010]).
New developments in the treatment of primary insomnia in elderly patients: focus on prolonged-release melatonin

Daniel P Cardinali
Maria F Vidal
Daniel E Vigo

Department of Teaching and Research, Faculty of Medical Sciences, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina

Abstract: A temporal relationship between the nocturnal rise in melatonin secretion and the increase in sleep propensity at the beginning of the night, coupled with the sleep-promoting effects of exogenous melatonin, indicate that melatonin is involved in the regulation of sleep. This action is attributed to the MT₁ and MT₂ melatonin receptors present in the hypothalamic suprachiasmatic nucleus and other brain areas. The sleep-promoting actions of melatonin, which are demonstrable in healthy humans, have been found to be useful in subjects suffering from circadian rhythm sleep disorders and in elderly patients, who had low nocturnal melatonin production and secretion. The effectiveness of melatonin in treating sleep disturbances in these patients is relevant because the sleep-promoting compounds that are usually prescribed, such as benzodiazepines and related drugs, have many adverse effects, such as next-day hangover, dependence, and impairment of memory. Melatonin has been used for improving sleep in patients with insomnia mainly because it does not cause any hangover or show any addictive potential. However, there is a lack of consistency concerning its therapeutic value (partly because of its short half-life and the small quantities of melatonin used). Thus, attention has been focused either on the development of more potent melatonin analogs with prolonged effects or on the design of slow-release melatonin preparations. A prolonged-release preparation of melatonin 2 mg (Circadin®) has been approved for the treatment of primary insomnia in patients aged ≥55 years in the European Union. This prolonged-release preparation of melatonin had no effect on psychomotor functions, memory recall, or driving skills during the night or the next morning relative to placebo, and was associated with significantly less impairment on many of these tasks relative to zolpidem alone or in combination with prolonged-release melatonin. In 3-week and 6-month randomized, double-blind, clinical trials in patients with primary insomnia aged ≥55 years, prolonged-release melatonin was associated with improvements relative to placebo in many sleep and daytime parameters, including sleep quality and latency, morning alertness, and quality of life. Prolonged-release melatonin was very well tolerated in clinical trials in older patients, with a tolerability profile similar to that of placebo. Short-term or longer-term treatment with prolonged-release melatonin was not associated with dependence, tolerance, rebound insomnia, or withdrawal symptoms.

Keywords: insomnia, melatonin, Circadin®, clinical trials

Introduction

Insomnia is a common disorder, the definition of which is not clearly settled as yet. It is a condition of unsatisfactory sleep, either in terms of sleep onset, sleep maintenance, or early waking. It is also a disorder that affects daytime and subjective well-being, skills, and performance. Like pain, insomnia is a subjective disorder amenable to diagnosis through clinical observations rather than through objective measurements.
Insomnia may begin with a specific problem, for example, a stressful life event, and in some people, the acute insomnia episode progresses to a chronic state. Factors involved in the persistence of insomnia include iteration of precipitating stress, anxiety about sleep, maladaptive sleep habits, or an intrinsic vulnerability of the neural mechanism regulating sleep. Insomnia is often comorbid with other psychiatric disorders, especially anxiety and depression, or with physical illness, such as cancer or arthritis.

Epidemiological surveys indicate that up to 40% of individuals over 65 years of age are dissatisfied with their sleep or report trouble in initiating and maintaining sleep, and that 12%–25% complain of persistent insomnia. This leads to increased use of hypnotics by older adults, which is a cause for concern. Up to 30%–40% of seniors use a sedative-hypnotic benzodiazepine or related medication, and frequently show side effects from hypnotics due to both increased nervous system sensitivity and decreased serum albumin (that binds the drugs). Thus, older patients respond to drugs differently and less predictably than their younger counterparts.

In aging individuals, a combination of altered sleep and sleep pathologies increases the risk of drug-induced insomnia or excessive diurnal somnolence. Pharmacokinetic and pharmacodynamic changes due to progressive aging and comorbid medical problems can make treatment more difficult and potentially risky. Many older adult patients are treated for longer periods or with higher dosages of hypnotic drugs than are recommended, generally with a lack of individual dosage titration.

Several studies have shown the importance of melatonin both for initiation and maintenance of sleep, and this has been reviewed elsewhere. In human beings, the onset of melatonin secretion coincides with the timing of the increase in propensity for nocturnal sleep. Measurements of melatonin in body fluids in elderly subjects have demonstrated convincingly an age-related impairment of nocturnal pineal melatonin synthesis. Because melatonin exhibits both hypnotic and chronobiotic properties, it has been used for treatment of age-related insomnia as well as of other primary and secondary insomnia. Melatonin has also been used successfully for treatment of sleep problems related to perturbations of the circadian time-keeping system, like those caused by jet-lag, shift work disorder, or delayed sleep phase syndrome.

Because melatonin has a short half-life, its efficacy in promoting and maintaining sleep has not been uniform in the studies undertaken so far. Thus, the need arose for the development of prolonged-release preparations of melatonin or of melatonin agonists with a longer duration of action on sleep regulatory structures in the brain. A prolonged-release form of melatonin known as Circadin, a 2 mg preparation developed by Neurim Pharmaceuticals, Tel Aviv, Israel, was approved by the European Medicines Agency in 2007 for the treatment of insomnia in patients ≥ 55 years of age.

This review focuses on the data published concerning this prolonged-release melatonin preparation in the context of recent developments on melatonin physiology. The relevant medical literature was identified by searching the Medline and Embase databases, bibliographies from the published literature, and clinical trial registries and databases. The searches were last updated on August 5, 2012.

Benzodiazepines and related drugs in insomnia

Benzodiazepines exert sedative actions through activation of BZ1 and BZ2 receptor subtypes of the gamma-aminobutyric acid (GABA) complex, with activation of BZ2 accounting for their specific hypnosedative, anxiolytic, and anticonvulsant activities. The α1-subunit of the GABA receptor mediates the sedative and anxiolytic effects of benzodiazepines. The efficacy of benzodiazepines in treating insomnia was supported by several meta-analyses, with one including 22 studies, which indicated that benzodiazepines increase total sleep time, improve total sleep quality, and reduce sleep onset latency. However, benzodiazepines also have significant adverse effects, including cognitive and psychomotor impairment, anterograde amnesia, next-day hangover, and rebound insomnia. Because of their adverse effects, use of benzodiazepines for the treatment of insomnia in the elderly has become controversial.

Nonbenzodiazepine drugs like zolpidem, zaleplon, and zopiclone all have high affinity and selectivity for the α1-subunit of the GABA receptor complex. Zolpidem improves sleep maintenance shortly after administration, but the effect disappears at a later stage. It may cause adverse effects like daytime drowsiness, dizziness, headache, and nausea. Zaleplon, a pyrazolopyrimidine derivative, is effective for decreasing sleep onset latency and improving sleep quality, and because of its efficacy and safety, it is advocated for treating subjects with sleep initiation difficulties. Zopiclone and its active stereoisomer, eszopiclone, have both been shown to be effective and safe in patients with primary insomnia. In general, nonbenzodiazepine sedative hypnotics, although effective in
Reducing sleep onset latency, are only moderately effective in increasing sleep efficiency and total sleep time.30

Indeed, an ideal hypnotic drug should not only decrease sleep onset latency but should also increase total sleep time and sleep efficiency.1 In addition, the ideal hypnotic should not produce undesired effects, such as impairment of memory, cognition, psychomotor retardation, and next-day hangover effects, or have the potentiality of abuse.

Melatonin and insomnia
The sleep-promoting activity of melatonin in humans has been known for years.31,32 A number of studies have pointed to a beneficial effect of melatonin in a wide variety of sleep disorders.10,11,33,34 However, controversy continues to surround claims of the therapeutic potential of melatonin. A meta-analysis of the effects of melatonin on sleep disturbances in all age groups (including young adults with presumably normal melatonin levels) failed to document significant and clinically meaningful effects of exogenous melatonin on sleep quality, efficiency, and latency.35 However, another meta-analysis involving 17 controlled studies in older subjects has shown that melatonin was effective in increasing sleep efficiency and reducing sleep onset latency.36 A recent consensus from the British Association for Psychopharmacology on evidence-based treatment of insomnia, parasomnia, and circadian rhythm sleep disorders concluded that melatonin is the first choice treatment when a hypnotic is indicated in patients over 55 years.1

Studies carried out using 0.3–1 mg doses of melatonin, that produced physiological melatonin levels in the circulation, have shown that melatonin reduced sleep onset latency and increased sleep efficiency when administered to healthy human subjects in the evening.37,38 However, in most studies, higher amounts of melatonin (2–6 mg) need to be given to obtain effects. Brain imaging studies in awake subjects have revealed that melatonin modulates the brain activity pattern to one resembling that of actual sleep.39

Basic physiology of melatonin
Although melatonin is synthesized in a wide variety of tissues, circulating melatonin comes almost entirely from the pineal gland.40 Synthesis of melatonin in the pineal gland is regulated by the master clock in the hypothalamic suprachiasmatic nucleus; under certain circumstances, like exposure to light at night, this clock signal can be overridden downstream from the clock by visual inputs which suppress melatonin synthesis.

Melatonin metabolism
Because melatonin is a lipophilic substance, once it is synthesized in the pineal gland, it diffuses readily into the bloodstream, where it is bound to albumin.41 Melatonin rapidly disappears from the blood, with a half-life that is biexponential, with a first distribution half-life of 2 minutes and a second of 20 minutes.42

Circulating melatonin is metabolized mainly in the liver, which clears 92%–97% of circulating melatonin in a single pass.43 Melatonin is first hydroxylated in the C6 position by cytochrome P450 (CYP) mono-oxygenases (isozymes CYP1A2, CYP1A1, and, to a lesser extent, CYP1B1), and thereafter is conjugated with sulfate to be excreted as 6-sulfatoxymelatonin, with glucuronide conjugation being extremely limited.42 CYP2C19 and, at lower rates, CYP1A2, also demethylate melatonin to its precursor, N-acetylserotonin.44

Tissues of neural origin, including the pineal gland and retina, contain melatonin-deacetylating enzymes, which are either specific melatonin deacetylases or less specific aryl acylamidases.40 Melatonin metabolism in the brain involves oxidative pyrrole ring cleavage. The primary cleavage product is N-1-acetyl-N-2-formyl-5-methoxykynuramine (AFMK), which is deformedylated, either by arylamine formamidase or hemoperoxidase, to N-1-acetyl-5-methoxykynuramine (AMK). Some estimations indicate that pyrrole ring cleavage contributes to about one third of the total catabolism of melatonin, but the percentage may be even higher in certain tissues. Other oxidative catabolites are cyclic 3-hydroxymelatonin, which can also be metabolized to AFMK, and a 2-hydroxylated analog, which does not cyclize but turns into an indolinenone.40 A dithional hydroxylated or nitrosated metabolites have been detected, but they appear to be present in minor quantities only.

AFMK and N-1-acetyl-5-methoxykynuramine form metabolites by interaction with reactive oxygen and nitrogen species. AFMK is produced by numerous nonenzymatic and enzymatic mechanisms,40 and its formation by myeloperoxidase appears to be important in quantitative terms.45 Antioxidative protection, safeguarding of mitochondrial electron flux and, in particular, neuroprotection, have been demonstrated in many experimental systems to be mediated by melatonin and its endogenous metabolites.

Melatonin receptors
Binding sites for melatonin were initially identified in a wide variety of central and peripheral tissues using 3H-melatonin46,47 and later 2-I 125-iodomelatonin.48 Molecular cloning of the
first high affinity membrane melatonin receptor (MT₁) was accomplished using a cDNA library constructed from a dermal cell line of melanophores, the first tissue in which the action of melatonin had been demonstrated. This initial finding led to the discovery that there are at least two G₁ protein-coupled membrane melatonin receptors in humans. The second receptor (MT₂) is 60% identical in its amino acid sequence to the MT₁ receptor. Yet a third receptor, now called GPR50, shares 45% of the amino acid sequence with MT₁ and MT₂, but does not bind melatonin.

In the mammalian brain, MT₁ and MT₂ receptors have been reported in the suprachiasmatic nucleus, prefrontal cortex, cerebellar cortex, hippocampus, basal ganglia, substantia nigra, ventral tegmental area, nucleus accumbens, retinal horizontal, amacrine, ganglion cells, and the choroid plexus, and have been discussed elsewhere. The MT₁ receptor is highly expressed in the human suprachiasmatic nucleus and mainly in vasopressinergic neurons, a finding that could be critical, given that the release of vasopressin is one of the important constituents of circadian output from the suprachiasmatic nucleus.

MT₂ was not detected in an earlier investigation of the human suprachiasmatic nucleus. This receptor subtype is expressed in the suprachiasmatic nucleus of many mammals and, where present, is particularly important for circadian phase shifting. Exclusion of purely technical reasons for lack of detection of the MT₂ receptor in the human suprachiasmatic nucleus (eg, a very low level of expression) is crucial for the design of new melatonergic drugs in therapy. Indeed, circadian clock reset does occur in humans after administering melatonin, and to disclose whether these changes are induced by exclusive MT₁ signaling is of utmost importance. Circadian phase shifting by melatonin is possible in other species in which MT₂ receptors have been lost in the course of evolution.

The binding of melatonin to transcription factors of the retinoic acid receptor superfamily, including RORα isoforms α, β, and δ (formerly called RZRα), and the product of another gene, RORβ or RZRβ, are increasingly considered as being physiologically important. Some of these transcription factors interact with circadian core oscillators, thereby influencing phasing, resetting, and period lengths of circadian rhythms. In the mammalian brain, expression of RORα subforms and RORβ is detectable in the suprachiasmatic nucleus and other parts of the hypothalamus, the thalamus, pineal gland, retina, spinal cord, and pars tuberalis. Remarkably, the RORβ signal is highest in areas of highest MT₁ receptor density, suggesting the possibility that some sort of cooperation exists between the membrane and nuclear receptors, especially in areas containing circadian oscillators. RORβ knockout mice exhibited significant circadian changes, eg, larger phase advance and slower resynchronization than wild-type mice.

MT₁-mediated effects in the suprachiasmatic nucleus favor sleep initiation via the hypothalamic sleep switch, a structure characterized by typical on-off responses. This switch is thought to activate either wake-related neuronal downstream pathways or promote the sleep-related ones alternately. Actions via the sleep switch do not seem to represent the exclusive route of melatonin-induced sleep onset. This is not surprising given that sleep and also sleep initiation are complex phenomena in which various brain areas are involved. The thalamus in particular contributes to the soporific effects of melatonin by promoting spindle formation, a characteristic feature of the transition from stage 2 sleep to deeper sleep stages. This requires an additional thalamocortical interplay known to occur under these conditions. Moreover, the thalamus and other brain areas feed back to the suprachiasmatic nucleus.

In addition to sleep promotion, MT₁ and MT₂ receptors appear to be involved in the sedating and anticonvulsant effects of melatonin. This has been mainly studied in relation to anticonvulsant actions, which have been linked to a facilitatory role of melatonin in GABAergic transmission. The anticonvulsant activity of melatonergic agents seems to be mediated by MT₁ and/or MT₂ membrane receptors because similar effects were observed with the MT₁/MT₂ agonist, ramelteon. In mammals, the anticonvulsant actions may also be related to the additional anxiolytic, antihyperalgesic, and antiglaucomatous effects of melatonergic agents.

**Clinical pharmacology of prolonged-release melatonin**

Table 1 summarizes the relevant information on the efficacy of prolonged-release melatonin in the improvement of sleep quality in patients with primary insomnia. An initial study concerned its efficacy in 12 outpatients aged 68–93 years with insomnia who were taking benzodiazepines and had a low urinary 6-sulfatoxymelatonin output. In this randomized, double-blind, placebo-controlled crossover study, prolonged-released melatonin 2 mg/day increased sleep efficiency and total sleep time and decreased wake after sleep onset, sleep latency, number of awakenings, and the fragmental index as assessed by actigraphy. A further study with a similar design replicated the initial findings.
Given that, as mentioned earlier, melatonin and benzodiazepines share some neurochemical (ie, interaction with GABA-mediated mechanisms in the brain) and behavioral (eg, a similar day-dependent anxiolytic activity) properties, melatonin therapy was postulated as an effective tool to decrease the benzodiazepine dose. As early as 1997, two observations pointed to a possible beneficial effect of melatonin in this respect. We reported an open-label study showing that eight of 13 patients with insomnia either discontinued or reduced their benzodiazepine use by 50%-75% after taking a 3 mg dose of rapid-release melatonin. Dagan et al published a case report on the efficacy of 1 mg of controlled-release melatonin in ceasing any benzodiazepine use completely in a 43-year-old woman who had suffered from insomnia for the previous 11 years.

In a double-blind, placebo-controlled study followed by a single-blind period in 34 outpatients aged 40–90 years with primary insomnia who took benzodiazepines and had low urinary 6-sulfatoxymelatonin levels, 14 of 18 subjects who had received prolonged-release melatonin, but only four of 16 in the placebo group, discontinued benzodiazepine therapy (Table 1). An open-label study further supported the efficacy of rapid-release melatonin to decrease benzodiazepine use, ie, 13 of 20 patients with insomnia taking benzodiazepines together with melatonin 3 mg could stop benzodiazepine use, while another four patients decreased their benzodiazepine dose to 25%-66% of initial doses.

These observations were not supported by the results of a placebo-controlled study in 38 long-term benzodiazepine users, 40% of whom had stopped their benzodiazepine use after one year, both in the intervention group receiving melatonin and in the placebo control group. It must be noted that, on many occasions, older patients with minor sleep disturbance received anxiolytic benzodiazepines or sedative-hypnotic benzodiazepines in low doses on a long-term basis. To assess the efficacy of melatonin in reducing the use of benzodiazepines at very low doses, we carried out a double-blind, placebo-controlled study of 45 patients randomized to receive either rapid-release melatonin 3 mg or placebo for 6 weeks. The benzodiazepine was tapered off in two steps and stopped after 4 weeks. Several sleep parameters were assessed and found not to be different in either group. That the patients included in our study were taking benzodiazepines for reasons other than an established sleep disturbance was indicated by the lack of subjective changes in sleep quality after reduction or suppression of the benzodiazepine dose. However, melatonin was not devoid of activity; it advanced sleep onset and decreased variability of sleep onset time significantly when compared with placebo.

A recent retrospective analysis of a German prescription database identified 512 patients who had initiated treatment with prolonged-release melatonin 2 mg over a 10-month period. Of 112 patients in this group who had previously used benzodiazepines, 31% discontinued treatment with benzodiazepines 3 months after starting prolonged-release melatonin treatment. The discontinuation rate was higher in patients receiving two or three melatonin prescriptions. Therefore, prolonged-release melatonin can help to facilitate discontinuation of benzodiazepines in older insomniacs.

The efficacy of prolonged-release melatonin in the treatment of insomnia in older patients is supported by the results of both Phase III and IV trials (Table 1). Two double-blind, placebo-controlled trials including 170 and 354 outpatients aged ≥55 years with primary insomnia indicated a significant improvement in quality of sleep and morning alertness, and in quality of life as well as shortening of sleep latency after 3 weeks of treatment with prolonged-release melatonin 2 mg (Table 1). No rebound insomnia or withdrawal effects were seen.

Similar results were reported for a clinically relevant subgroup of 578 patients aged ≥55 years in a randomized, 3-week, double-blind trial, followed by a 26-week, double-blind extension period in which patients were randomized to receive melatonin or placebo, followed by a 2-week, single-blind, placebo withdrawal period. The primary endpoint in this trial was change from baseline in sleep latency at the end of the initial 3-week treatment period in the predefined subgroups of patients with low endogenous levels of urinary melatonin. In patients aged ≥65 years (n = 281), melatonin decreased sleep latency regardless of the extent of 6-sulfatoxymelatonin excretion. The effect of prolonged-release melatonin in patients with low urinary 6-sulfatoxymelatonin levels regardless of age did not differ from placebo. Improvement of sleep and daytime parameters was maintained or enhanced over a 6-month period, with no signs of tolerance. Most adverse events were mild in severity and showed no clinically relevant differences from placebo, including endocrine parameters (prolactin, adrenocorticotropic hormone, thyroid hormones, thyroid-stimulating hormone, luteinizing hormone, follicle-stimulating hormone, estradiol, free and total testosterone, and cortisol).

A prospective open-label study in 244 community-dwelling adults with primary insomnia (mean age 55.3 years) who received prolonged-release melatonin 2 mg for 6–12 months was recently published. Sleep diary, adverse events,
Table 1 Relevant clinical studies on prolonged-release melatonin in primary insomnia

<table>
<thead>
<tr>
<th>Condition</th>
<th>Type of study</th>
<th>n</th>
<th>Daily melatonin dose</th>
<th>Duration of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary insomnia outpatients aged 76 ± 8 (68–93) years who took BZP and had low urinary 6-sulfatoxymelatonin levels</td>
<td>Randomized, double-blind, placebo-controlled, crossover study</td>
<td>12</td>
<td>2 mg</td>
<td>3 weeks with melatonin or placebo, followed by one-week washout, and then crossed over for another 3 weeks</td>
</tr>
<tr>
<td>Primary insomnia outpatients aged 79 ± 5.2 (68–93) years under BZP treatment and having low urinary 6-sulfatoxymelatonin levels</td>
<td>Randomized, double-blind, placebo-controlled, crossover study</td>
<td>21</td>
<td>2 mg</td>
<td>3 weeks with melatonin or placebo, followed by one-week washout, and then crossed over for another 3 weeks</td>
</tr>
<tr>
<td>Primary insomnia outpatients aged 40–90 years who took BZP and had low urinary 6-sulfatoxymelatonin levels</td>
<td>Randomized, double-blind, placebo-controlled study followed by a single-blind period</td>
<td>34</td>
<td>2 mg</td>
<td>Patients received melatonin or placebo for 6 weeks. They were encouraged to reduce BZP dose 50% during week 2, 75% during weeks 3 and 4, and to discontinue BZP during weeks 5 and 6. Then melatonin was administered (single-blind) for 6 weeks and attempts to discontinue BZP therapy were resumed; follow-up reassessment was performed 6 months later</td>
</tr>
<tr>
<td>Primary insomnia outpatients aged ≥55 years</td>
<td>Double-blind, placebo-controlled trial</td>
<td>170</td>
<td>2 mg</td>
<td>3 weeks</td>
</tr>
<tr>
<td>Primary insomnia outpatients aged ≥55 years</td>
<td>Double-blind, placebo-controlled trial</td>
<td>354</td>
<td>2 mg</td>
<td>3 weeks</td>
</tr>
<tr>
<td>Healthy volunteers aged ≥55 years</td>
<td>Randomized, double-blind, placebo-controlled, single-dose, four-way crossover study</td>
<td>16</td>
<td>2 mg, zolpidem 10 mg, and their combination</td>
<td>Subjects were tested one and 4 hours and next morning after dosing</td>
</tr>
<tr>
<td>Primary insomnia outpatients aged 55–68 years</td>
<td>Double-blind, placebo-controlled trial</td>
<td>40</td>
<td>2 mg</td>
<td>3 weeks</td>
</tr>
<tr>
<td>Primary insomnia outpatients aged 18–80 years</td>
<td>Randomized, double-blind, parallel-group, clinical trial</td>
<td>791</td>
<td>2 mg</td>
<td>3-week double-blind treatment, followed by a 26-week, double-blind, extension period with patients randomized to receive melatonin or placebo, followed by a 2-week, single-blind, placebo withdrawal period</td>
</tr>
<tr>
<td>Community-dwelling adults with primary insomnia of mean age 55.3 years</td>
<td>Prospective open-label study</td>
<td>244</td>
<td>2 mg</td>
<td>6–12 months</td>
</tr>
<tr>
<td>Perimenopausal women with insomnia aged 45–52 years</td>
<td>Open-label, case series</td>
<td>11</td>
<td>2 mg</td>
<td>Treated with mirtazapine 15 mg for 2–4 weeks. Melatonin was then added on, and mirtazapine was tapered off for another 1–3 months</td>
</tr>
</tbody>
</table>
Primary insomnia outpatients aged 40–90 years who took BZP and had low urinary 6-sulfatoxymelatonin levels.

Healthy volunteers aged 18–80 years.

Table

<table>
<thead>
<tr>
<th>Condition</th>
<th>Type of study</th>
<th>n</th>
<th>Daily duration</th>
<th>Outcome measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary insomnia</td>
<td>Placebo</td>
<td>170</td>
<td>2 mg</td>
<td>Sleep quality was objectively monitored by wrist actigraphy.</td>
</tr>
<tr>
<td></td>
<td>Treated</td>
<td>791</td>
<td>2 mg</td>
<td>Sleep assessed by wrist actigraphy. Urinary 6-sulfatoxymelatonin measurement.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>79</td>
<td>2 mg</td>
<td>Sleep diary and recording of BZP use.</td>
</tr>
<tr>
<td>Perimenopausal women</td>
<td>Open-label</td>
<td>354</td>
<td>2 mg</td>
<td>Quality of sleep and morning alertness assessed by Leeds Sleep Evaluation Questionnaire.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>21</td>
<td>2 mg</td>
<td>Sleep diary, Pittsburgh Sleep Quality Index global score, Quality of Night and Quality of Day derived from a sleep diary, Clinical Global Improvement scale and quality of life (WHO-5 well being index)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16</td>
<td>2 mg, zolpidem</td>
<td>Psychomotor functions, memory recall, and driving skills.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10</td>
<td>2 mg</td>
<td>Polysomnography and EEG spectral analysis.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Psychomotor performance assessed by the Leeds Psychomotor Test battery.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sleep diary, Pittsburgh Sleep Quality Index, Quality of Life (World Health Organzation-5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical Global Impression of Improvement assessment, urinary 6-sulfatoxymelatonin and adverse effects and vital signs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sleep diary, adverse events, vital signs, laboratory tests, and withdrawal symptoms. Nocturnal urinary 6-sulfatoxymelatonin excretion assessed upon discontinuing treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Body weight data. Subjective assessment of sleep quality and well-being.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(Pittsburgh Sleep Quality Index and Well-Being Index, WHO-5)</td>
</tr>
</tbody>
</table>

- Significant improvement in quality of sleep and morning alertness.
- The improvements in quality of sleep and morning alertness were strongly correlated. No rebound insomnia or withdrawal effects were seen.
- Significant improvements in quality of sleep and morning alertness and in quality of life. Shortening of sleep latency.
- No impairment of performance after melatonin. Zolpidem impaired psychomotor and driving performance one and 4 hours post-dosing, and early memory recall. Melatonin coadministration exacerbated zolpidem effect.
- Shorter sleep onset latency as compared to placebo.
- Significantly better scores in the Critical Flicker Fusion Test.
- 50% of patients reported substantial improvement in sleep quality at home. No rebound insomnia or withdrawal effects.
- In patients aged ≥65 years (n = 281) melatonin decreased sleep latency regardless of 6-sulfatoxymelatonin excretion.
- Effect in patients with low urinary 6-sulfatoxymelatonin levels regardless of age did not differ from placebo. Improvement of sleep and daytime parameters maintained or enhanced over a 6-month period with no signs of tolerance. Most adverse events were mild in severity with no clinically relevant differences with placebo, including endocrine parameters.
- Of the 244 patients, 36 dropped out, 112 completed 6 months of treatment, and 96 completed 12 months of treatment. The mean number of nights reporting sleep quality as “good” or “very good” was significantly higher during treatment. There was no evidence of tolerance and discontinuation was not associated with rebound insomnia or withdrawal symptoms. No suppression of endogenous melatonin production.
- Significant improvement in sleep quality and well-being during combined mirtazapine and melatonin intake and during subsequent intake of melatonin alone or together with very low doses of mirtazapine, 5 of 7 women demonstrating weight gain following mirtazapine intake started to reduce weight after melatonin treatment.

(Continued)
vital signs, laboratory tests, and withdrawal symptoms, as well as nocturnal urinary 6-sulfatoxymelatonin excretion were assessed upon discontinuing treatment. Of the initial 244 patients, 36 dropped out, 112 completed 6 months of treatment, and 96 completed 12 months of treatment. The mean number of nights reporting sleep quality as “good” or “very good” was significantly higher during treatment. There was no evidence of tolerance, and discontinuation was not associated with rebound insomnia or withdrawal symptoms. No suppression of endogenous melatonin production was found.

A objective evaluation of sleep in patients on prolonged-release melatonin treatment was undertaken using polysomnography in a double-blind, placebo-controlled study including 40 outpatients aged 55–68 years with primary insomnia and receiving treatment for 3 weeks. Treated patients showed shorter sleep onset latency and better psychomotor performance as assessed in the Critical Flicker Fusion Test of Leeds Psychomotor test battery.

Specific groups of insomnia patients, eg, those with diabetes, seem to benefit from treatment with prolonged-release melatonin. In a randomized, double-blind, placebo-controlled, crossover study in type 2 diabetic patients with insomnia aged 46–77 years, actigraphy showed that sleep efficiency, wake time after sleep onset, and number of awakenings improved significantly. Although none of the blood parameters changed after 3 weeks of treatment with melatonin, glycosylated hemoglobin levels decreased after 5 months of treatment.

Indeed, an area of interest in the potential applications of melatonin is the metabolic syndrome. A number of studies have indicated that melatonin has the ability to reduce obesity, type 2 diabetes, and liver steatosis in experimental animals.

Low levels of circulating melatonin occur in patients with type 2 diabetes, concomitant with upregulation of mRNA expression of the melatonin membrane receptor. In addition, variants in the gene encoding the melatonin receptor have been associated with fasting blood glucose levels and increased risk of type 2 diabetes.

Other aspects of the metabolic syndrome are also linked to abnormal melatonin secretion. Night-time melatonin supplementation reduced nocturnal blood pressure in otherwise untreated hypertensive men, nondipping women, patients with nocturnal hypertension, and adolescents with type 1 diabetes mellitus. Improvement in the lipid profile after melatonin treatment has also been observed in human studies. An open-label study of the effect of melatonin in patients with the metabolic syndrome phenotype indicates that melatonin 5 mg/day for 2 months significantly decreased high blood pressure, improved the serum lipid profile, and reduced antioxidative status.

A other group of patients who may benefit from treatment with prolonged-release melatonin is perimenopausal women with insomnia. A group of such patients, aged 45–52 years, was studied in an open-label case series (Table 1). In 11 perimenopausal women who received 2 mg of prolonged release melatonin together with 15 mg mirtazapine for 2–4 weeks and who were tapered off mirtazapine for another 1–3 months, a significant improvement in sleep quality and well-being during combined mirtazapine and melatonin intake and during subsequent intake of melatonin alone was detected. Five of seven women demonstrating weight gain following treatment with mirtazapine started to lose weight after treatment with melatonin. Further studies are needed.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Type of study</th>
<th>n</th>
<th>Daily melatonin dose</th>
<th>Duration of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2 diabetic patients with insomnia aged 46–77 years</td>
<td>Randomized, double-blind, placebo-controlled, crossover study</td>
<td>36</td>
<td>2 mg</td>
<td>3 weeks with melatonin or placebo, followed by one-week washout, and then crossed over for another 3 weeks. Extension period of 5 months giving melatonin to all patients in an open-label design</td>
</tr>
<tr>
<td>Healthy volunteers, aged 55–64 years</td>
<td>Randomized, double-blind, placebo-controlled, single-dose, three-way crossover study</td>
<td>24</td>
<td>2 mg, zolpidem</td>
<td>Subjects were tested 30 minutes before and 1.5 and 4 hours after dosing</td>
</tr>
<tr>
<td>Patients classified according to their use of hypnotic BZP or BZP-like drugs</td>
<td>Retrospective study from a longitudinal database</td>
<td>112</td>
<td>2 mg</td>
<td>Varied intervals</td>
</tr>
</tbody>
</table>

*Abbreviations: BZP, benzodiazepine; EEG, electroencephalography.*
to evaluate gender differences in response to treatment with prolonged-release melatonin for insomnia.

Two studies have been undertaken in healthy volunteers to compare the effect of prolonged-release melatonin with that of zolpidem. In a double-blind, placebo-controlled, single-dose, four-way crossover study, 16 healthy volunteers aged ≥55 years were randomized to prolonged-release melatonin or zolpidem 10 mg, or a combination of the two agents. Subjects were tested at one hour, four hours, and the morning after dosing. Psychomotor functioning, memory recall, and driving skills were assessed. No impairment of performance was detected after melatonin, whereas zolpidem impaired psychomotor and driving performance one and four hours post-dosing as well as early memory recall. Melatonin coadministration potentiated the effect of zolpidem.

In another study, the effects of prolonged-release melatonin and zolpidem on postural stability were assessed in healthy older adults. Twenty-four volunteers, aged 55–64 years, were randomized in a double-blind, placebo-controlled, single-dose, three-way crossover study. Body sway was tested by the area of the 95% confidence ellipse enclosing the center of pressure (A95) and its path length. No effect of melatonin on A95 was detected. In contrast, zolpidem significantly increased the A95 and path length, pointing to the possibility of postural disturbance caused by the drug.

One important point to address when using a prolonged-release formulation of melatonin, eg, Circadin, is how it is related to the phase response curve of methoxyindole. Presumably significant amounts of melatonin will be present at both the phase advance (early night) and phase delay (early morning) parts of the sensitivity curve. Considering that elderly patients are more often phase advanced, it would be of the utmost importance to assess whether the beneficial effect of melatonin on insomnia depends on a phase-delaying effect on the circadian rhythm (by acting like a small morning dose of melatonin, which has been proposed to delay the circadian rhythm).

### Safety and place in therapy

Prolonged-release melatonin has an excellent safety and tolerability record, showing no difference from placebo. Emergent adverse events, including gastrointestinal, cardiovascular, and body weight changes have been absent. Indeed, melatonin is usually remarkably well tolerated and, in some studies, has been administered to patients in very large doses. Melatonin 10 mg/day decreased interleukin-6 levels in patients with cancer and 300 mg/day doses for up to 3 years decreased oxidative stress in patients with amyotrophic lateral sclerosis. In children with muscular dystrophy, melatonin 70 mg/day reduced cytokine levels and lipid peroxidation. Melatonin doses of 80 mg/hour for 4 hours were given to healthy men with no undesirable effects, other than drowsiness. There were no side effects in healthy women given melatonin 300 mg/day for 4 months.

A recent randomized, controlled, double-blind clinical trial in 50 patients referred for liver surgery indicates that a single preoperative enteral melatonin dose of 50 mg/kg was safe and well tolerated. A nother important point to consider when dealing with high amounts of melatonin is that, in addition to its low toxicity, it is a potent multiple mitochondrial protector.

The ultimate goal of treatment for insomnia is symptomatic and functional recovery that helps a return to everyday life. However, a large proportion of patients on treatment with benzodiazepines fail to achieve a complete

### Table

<table>
<thead>
<tr>
<th>Outcome measures</th>
<th>Response</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sleep monitoring by actigraphy. Measuring of fasting glucose, fructosamine, insulin, C-peptide, triglyceride, total cholesterol, high-density and low-density lipoprotein cholesterol, antioxidants and glycosylated hemoglobin levels</td>
<td>Sleep efficiency, wake time after sleep onset, and number of awakenings improved significantly. No significant changes in blood parameters after 3 weeks of melatonin treatment. After 5 months of treatment, glycosylated hemoglobin levels decreased</td>
<td>88</td>
</tr>
<tr>
<td>Body sway tested by the area of the 95% confidence ellipse enclosing the center of pressure (A95) and its path length</td>
<td>No effect of melatonin on A95. It increased path length at 4 hours post-dose in open but not closed eyes condition. Zolpidem significantly increased the A95 and path length</td>
<td>89</td>
</tr>
<tr>
<td>Discontinuation rate of BZP</td>
<td>31% of patients discontinued BZP after melatonin initiation. The discontinuation rate was higher in patients receiving two or three melatonin prescriptions</td>
<td>90</td>
</tr>
</tbody>
</table>

**Abbreviations:** BZP, benzodiazepine; EEG, electroencephalography.
and sustained recovery and are left with residual symptoms that make relapse or recurrence more likely, and poorer quality of life a reality. Most treatment guidelines recognize a symptom-free state as the best definition of remission of insomnia, in spite of the fact that functional recovery often lags behind symptomatic improvement. Given the importance of all three dimensions of functioning (emotional, cognitive, and social) in everyday activities such as work, and the impact that daily functioning impaired by insomnia may have on a patient’s life, it is clear that more attention should be paid to functioning when assessing the response to treatment. In this respect, most safety concerns about use of hypnotics do not apply to prolonged-release melatonin, a fact recognized by the British Association for Psychopharmacology consensus statement on the evidence-based treatment of insomnia, parasomnias, and circadian rhythm disorders, that recommended prolonged-release melatonin as a first-line treatment for insomnia in patients aged 55 years and older.1

Conclusion
An important point when dealing with the effects of melatonin on sleep is to understand that they are different from those of the benzodiazepines and related drugs in that they exert a promoting effect on sleep by amplifying day/night differences in alertness and sleep quality, and display a modest sleep-inducing effect, which is quite mild as compared with that seen with the benzodiazepines. Because of their long history on the market and the lack of treatment alternatives for insomnia, the preconception on the part of the consumer is that a sleeping pill should be a strong inducer of sleep, something that the melatonin family of compounds will not accomplish. Therefore, a very important educational goal is to change this view because of the lack of negative effects (eg, addiction, dependence) with the melatonin analogs in comparison with well known complications of benzodiazepines.

It should be also be borne in mind that further studies using melatonin doses of 100 mg/day are needed to clarify the potential implications of the native melatonin compound in humans. From animal studies it is clear that a number of potentially useful effects of melatonin, like those in neurodegenerative disorders or in the metabolic syndrome, require administration of high doses of melatonin to become apparent. If one expects melatonin to be effective in improving health, especially in aged people, it is likely that the low doses of melatonin employed so far will not be very beneficial.

Acknowledgments
This research was supported by grants from the Agencia Nacional de Promocion Científica y Tecnológica, Argentina (PICT 2007-01045/2010-1465) and the Universidad de Buenos Aires (M 048). DPC and DEV are recipients of research career awards from the Argentine Research Council. MFV is a CONICET doctoral fellow.

Disclosure
The authors report no conflicts of interest in this work.

References


